September 14, 2022 | New Brunswick, NJ
With rapid transformation of cardiovascular medicine from reactive to preventive, the Rutgers Robert Wood Johnson University Hospital is investing in the vision of a technology-enabled cardiovascular service that will enhance all aspects of the patient journey by leveraging advanced technologies such as innovative devices, robotics and artificial intelligence (AI) capabilities.
Under leadership of Dr. Partho P. Sengupta, MD, MBBS, FACC, the Henry Rutgers Professor and the Chief of Division of Cardiology, the Center is designed to encourage a multidisciplinary approach where clinicians work with industry to investigate and apply new technologies, to solve medical problems. RCE is one of 5 companies invited to the grand opening of its Center for Innovation, located on the main campus of the hospital.
“We are thrilled for the opportunity to showcase our technology in enhancing clinical management for cardiovascular patients. We are currently working with the Robert Wood Johnson University Hospital, in evaluating the potential applications of a non-invasive approach to monitoring cardiac biomarkers. We look forward to showcasing RCE's platform, as we continue to build a collaborative relationship with Rutgers in finding optimal clinical applications that improve patient outcomes ,” stated Mr. Atandra Burman, CEO of RCE.
Learn more about the Center for Innovation and the collaboration at:
RCE Technolgies, Inc. is Carlsbad based medical technology company focused on improving clinical workflows for heart attack detection and monitoring. The company’s objective is to bring to market a non-invasive solution for the measurement of cardiac troponin - a cardiac injury biomarker, that can be applied as an aid in the diagnosis of myocardial infarctions (heart attacks) in busy emergency departments. The patented optical technology coupled with deep learning techniques fosters various clinical applications that allow the timely assessment of biomarkers in accelerating patient care workflows while reducing the cost burden to the health system. Recognized in 2021 by Texas Medical Center’s innovation cohort (TMCx), and winners at the pitch rounds at GaBio Summit 2020 and SEMDA 2019.